Molecular Comparison and Safety Profiles of Fezolinetant and Elinzanetant
Panelists discuss why elinzanetant is likely to be associated with a lower risk of liver injury due to its distinct molecular structure compared to fezolinetant, and compare the adverse event profiles of the 2 drugs, highlighting that elinzanetant is more commonly associated with headache and fatigue while fezolinetant is linked to abdominal pain, diarrhea, insomnia, and back pain.
- Why will elinzanetant likely be associated with a lower risk of liver injury?
(ie, molecular structure is very different from fezolinetant; liver toxicity is generally related to certain structural elements and not its receptor binding properties)
- How do the adverse event profiles differ among fezolinetant and elinzanetant?
Notes: In phase 3 clinical trials, headache and fatigue were the most common adverse events with elinzanetant. In a phase 3, 52-week safety study, The most common adverse events with fezolinetant were abdominal pain, diarrhea, insomnia, back pain, and hot flashes.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
